Completed PHASE1 INTERVENTIONAL 1-arm NCT01752257

EF5 in Melanoma Patients

Pilot Study to Characterize the HRHV Axis in the Microenvironment of Melanoma in Patients Undergoing Isolated Limb Infusion or Hypothermic Isolated Limb Perfusion With Melphalan

Sponsor: Douglas Tyler

Conditions Melanoma

Interventions EF5 Hypoxia

Updated 7 times since 2017 Last updated: Mar 6, 2015 Started: Jul 31, 2012 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01752257, this PHASE1 trial focuses on Melanoma and remains completed. Sponsored by Douglas Tyler, it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jan 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Douglas Tyler
Varian, a Siemens Healthineers Company

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States